ImageneBio (IMA) Q4 2024 earnings summary

Executive summary

• Completed a comprehensive strategic review, resulting in a merger agreement with Inmagene Biopharmaceuticals, expected to close mid-2025, with the combined company to focus on immunology and inflammatory indications.

• Discontinued development of IK-930 and prioritized IK-595, a dual MEK-RAF inhibitor, with 51 patients enrolled in Phase 1 trials as of year-end.

• Undertook significant workforce reductions and divested non-core assets, including legacy programs and intellectual property.

Financial highlights

• Net loss for 2024 was $49.2 million, a decrease from $68.2 million in 2023.

• Research and development expenses decreased 48% year-over-year to $30.9 million, reflecting program prioritization and workforce reductions.

• General and administrative expenses declined 5% to $23.7 million.

• Cash, cash equivalents, and marketable securities totaled $124.4 million as of December 31, 2024.

• No revenue from product sales; collaboration revenue with Bristol-Myers Squibb completed in 2023.

Outlook and guidance

• The merger with Inmagene is expected to close in mid-2025, with a $75 million equity investment contingent on closing.

• If the merger is not completed, the board may consider dissolution and liquidation.

• Cash runway is projected to fund operations for at least 12 months from the filing date, excluding merger completion.